Pennsylvania--(Marketwire - August 25, 2009) -

PuriCore New USD2.1 Million Facility 

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 25 August 2009 - PuriCore plc
(LSE: PURI), the life sciences company focused on developing and
commercialising proprietary, green solutions that safely, effectively,
and naturally kill infectious pathogens without causing harm to human
health or the environment, today announces that it has closed on a new
USD2.1 million debt facility with Republic First Bank. The debt will be
drawn down through the fourth quarter and is structured as a 36-month
promissory note with an imputed interest rate of 5.9%. This financing
is consistent with the company's strategy to utilize debt to fund the
installation of leased Sterilox Food Retail Systems.

Ben Brewerton        Greg Bosch, CEO 
Susan Quigley        Darren Weiss, VP of Finance 
Financial Dynamics   PuriCore
+44 (0) 20 7831 3113 +1 484 321 2700

About PuriCore

PuriCore plc (LSE: PURI) is a life sciences company focused on
developing and commercializing proprietary green solutions that safely,
effectively, and naturally kill infectious pathogens without causing
harm to human health or the environment. PuriCore's patented,
proprietary technology mimics the human body's production of the
natural antimicrobial hypochlorous acid, offering a safe and
non-hazardous approach to disinfection and sanitization. The Company's
products are used in a broad range of markets that depend upon
controlling contamination, including food retail and foodservice,
medical device disinfection, and wound care. Hypochlorous acid is
proven to be safe, environmentally friendly, and fast acting against a
broad range of infectious pathogens, including major public health
threats of C.difficile, E.coli, HIV, Human and Animal Influenza
(including H5N1 Avian Influenza), Legionella, MRSA, M.tuberculosis,
Norovirus, and Salmonella. PuriCore is headquartered
in Malvern, Pennsylvania, with offices in Stafford and Clevedon, UK. 

To receive additional information on PuriCore, please visit our website
at, which does not form part of this press release.

Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical facts
but rather are based on the Company's current expectations, estimates,
and projections about its industry; its beliefs; and assumptions. Words
such as 'anticipates,''expects,''intends,''plans,''believes,''seeks,''estimates,' and similar expressions are intended to identify
forward-looking statements. These statements are not guarantees of
future performance and are subject to known and unknown risks,
uncertainties, and other factors, some of which are beyond the
Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in the
forward-looking statements. The Company cautions shareholders and
prospective shareholders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company only
as of the date of this announcement. The forward-looking statements
made in this announcement relate only to events as of the date on which
the statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these forward-looking
statements to reflect events, circumstances, or unanticipated events
occurring after the date of this announcement except as required by law
or by any appropriate regulatory authority.

                    This information is provided by RNS
          The company news service from the London Stock Exchange


Contact Information: Contacts: RNS Customer Services 0044-207797-4400